With COVID-19 on the retreat, Coherus BioSciences sees the advantage wearing off for Amgen's pegfilgrastim injector kit.
With the pandemic tapering off in the United States and its sales force vaccinated, Coherus BioSciences, of Redwood City, California, hopes that returning its sales representatives to the field this spring will counter relatively flat sales of its pegfilgrastim biosimilar (Udenyca).
Udenyca is the company’s sole product thus far, and its market share has hovered around the 20% mark for about a year, while pricing competition from other products, including Amgen’s originator (Neulasta), and inventory buildups have caused revenues to decline to $83 million in the just-ended quarter from $116 million in the comparable year-ago quarter.
Turnaround Expected
Company CEO Dennis Lanfear said he anticipates a turnaround for Udenyca this year and the strength of additional product launches in coming years to drive revenues higher.
“Over the next 2 years, we anticipate bringing forward new products to market in the United States, complementing Udenyca in our commercial portfolio,” he said.
Coherus BioScience aims to bring 3 biosimilars to market, along with an anti–programmed death 1 (PD-1) antibody, toripalimab, which would target various solid tumors, the company said in its first quarter 2021 earnings statement (Table).
Click here to enlarge.
The company has ranibizumab (CHS-201), adalimumab (CHS-1420), and bevacizumab (CHS-305) biosimilar candidates in late-stage development. These would reference Lucentis, Humira, and Avastin, respectively.
Coherus reported a net loss of $173 million for the quarter, mainly because of a $145 million payment to Junshi Biosciences for the US and Canada marketing rights to toripalimab and charges associated with the recent cancellation of plans to bring an aflibercept ophthalmology biosimilar candidate (CHS-2020) to market. The product would have referenced Eylea.
Although the pegfilgrastim market grew 1% in the first quarter of 2021, revenues for Udenyca did not, and in an investor conference call, Lanfear attributed the declining sales and flat market share for Udenyca partly to pricing pressure from competing products, particularly the originator product Neulasta (Amgen), “which now has the lowest average sales price of any type of pegfilgrastim.”
Neulasta has a 67% share of the pegfilgrastim market, and Amgen has achieved a 55% market share for the Onpro wearable pegfilgrastim injector kit, Coherus officials stated. Paul Reider, executive vice president of commercial operations and market access for Coherus, predicted that Onpro dominance would now begin to deteriorate with the slackening pandemic and patients being able to visit their doctors more safely.
“Now that COVID-19 is receding, the medical imperative to use Onpro is greatly reduced,” he said.
Sales Calls Resume
Another reason the company is counting on increased Udenyca sales is that its sales force can get into the field again and make in-person visits.
“The majority of our field team has now been vaccinated and has resumed in-person sales calls,” Reider said.
The company hopes to have biosimilars referencing Lucentis, Humira, and Avastin on the market by 2023. A midyear 2021 biologics license application (BLA) filing is anticipated for the company’s ranibizumab candidate. The FDA has accepted the company’s BLA for the adalimumab biosimilar candidate, and FDA action is anticipated in December 2021. Lastly, a pharmacokinetics study is underway for Coherus’ bevacizumab candidate, although the pandemic has slowed patient enrollment and the BLA filing for this candidate has been pushed forward to the first part of 2022, Lanfear said.
Coherus said the FDA has granted breakthrough status for its toripalimab product, for which a BLA has been submitted with an FDA action anticipated in the first half of 2022.
For further reading about Coherus’ struggle to overcome the Onpro advantage, click here.
For an earlier story about Coherus and how the pandemic has influenced its operations, click here.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.